Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

GlobeNewswireFeb 28 17:00 ET

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $15 to $40

Moomoo NewsFeb 28 08:00 ET · Ratings

Keros Therapeutics Is Maintained at Overweight by Wells Fargo

Dow JonesFeb 27 12:18 ET · Ratings

Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns

TipRanksFeb 27 09:45 ET · Ratings

H.C. Wainwright Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $40

Moomoo NewsFeb 27 07:31 ET · Ratings

Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $26

Moomoo NewsFeb 27 07:31 ET · Ratings